Key result
MEOX1 was identified as a critical transcription factor mediating the switch from fibroblasts to pro-fibrotic myofibroblasts in heart failure, presenting a novel druggable target for cardiac fibrosis.
Single-cell genomic approaches have identified MEOX1 as a novel, cell-specific therapeutic target for reversing fibroblast activation in cardiac fibrosis.
Single-cell genomic technology has been used to identify MEOX1 as a potential cell-specific, druggable target in cardiac fibrosis. To this effect, a landmark study was recently published in Nature by Alexanian and colleagues. 1
No takes yet. Share an insight, caveat, or question.
Schumacher et al. (2021) conducted an editorial in Cardiac fibrosis. MEOX1 targeted therapy was evaluated. MEOX1 was identified as a critical transcription factor mediating the switch from fibroblasts to pro-fibrotic myofibroblasts in heart failure, presenting a novel druggable target for cardiac fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: